5/29
07:30 am
engn
enGene to Present at the Jefferies Global Healthcare Conference
Low
Report
enGene to Present at the Jefferies Global Healthcare Conference
5/15
04:05 pm
engn
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
Medium
Report
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
5/2
04:13 pm
engn
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting [Yahoo! Finance]
Low
Report
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting [Yahoo! Finance]
5/2
04:05 pm
engn
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
Low
Report
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
4/22
08:20 am
engn
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.
Low
Report
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.
4/15
08:11 am
engn
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $34.00 price target on the stock.
Low
Report
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $34.00 price target on the stock.
4/9
08:00 am
engn
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
Low
Report
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
3/28
09:07 am
engn
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $37.00 price target on the stock.
Low
Report
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $37.00 price target on the stock.
3/11
05:38 pm
engn
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress [Yahoo! Finance]
Low
Report
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress [Yahoo! Finance]
3/11
05:16 pm
engn
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
Low
Report
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
3/8
07:36 am
engn
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $40.00 price target on the stock.
Low
Report
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $40.00 price target on the stock.
3/5
07:00 am
engn
enGene To Present at the Leerink Partners Global Biopharma Conference
Low
Report
enGene To Present at the Leerink Partners Global Biopharma Conference